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Background: The best criteria for surfactant treatment in the perinatal period are unknown and this makes it of
interest to consider the possible economic implications of lessening the use of more restrictive criteria.
Objective: The objective of this study is the evaluation of the costs of respiratory care for preterm infants with
Respiratory Distress Syndrome (RDS) treated with “early rescue” surfactant compared to a "late rescue” strategy.
Methods: The study was carried out applying the costs of materials used, of staff and pharmacological therapy
calculated in the Neonatal Intensive Care Unit (NICU) of an Italian hospital to the Verder et al. study (Pediatrics
1999) clinical data.
Results: The cost for patients treated with early strategy was slightly lower than for patients treated with late
strategy (Euro 4,901.70 vs. Euro 4,960.07). The cost of treatment with surfactant was greater in the early group
(Euro 458.49 vs. Euro 311.74), but this was compensated by the greater cost of treatment with Mechanical
Ventilation (MV) in the late group (respectively Euro 108.85 vs. Euro 259.25).
Conclusions: The cost-effectiveness analysis performed in this study shows how early treatment with surfactant in
preterm infants with RDS, as well as being clinically more effective, is associated with a slightly lower cost.
Keywords: Surfactant, RDS, nCPAP, Cost-effectiveness, Preterm infantsIntroduction
The management of infant Respiratory Distress Syndrome
(RDS) involves artificial respiratory support and surfactant
treatment. Respiratory support includes nasal Continuous
Positive Airway Pressure (NCPAP) [1] and Mechanical
Ventilation (MV) [2], which are known for their effective-
ness in reducing mortality and morbidity caused by RDS.
However, MV is invasive and has the potential for injuring
the airways and lung parenchyma. Ventilator-induced lung
injury (VILI) may be associated with alveolar structural
damage, pulmonary oedema, inflammation, and fibrosis
[3], which are the histological features of bronchopulmon-
ary dysplasia (BPD). Thus, early treatment with NCPAP* Correspondence: roberto.ravasio@pharmes.it
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unless otherwise stated.[1] and surfactant [4] which decreases the need for MV
may be an effective strategy for reducing the incidence of
BPD in preterm infants with RDS [5-7].
Recently, some randomised controlled studies have in-
vestigated the issue of early respiratory management of
preterm infants [8-11], and in particular the role of
NCPAP and prophylaxis with surfactant in preventing MV
and decreasing mortality and/or BPD. A meta-analysis
based on some of these studies [10,11] concluded that
early treatment with NCPAP combined with the “rescue”
surfactant administration to infants requiring intubation
has similar effects to prophylactic surfactant treatment on
infants’ outcomes, supporting the use of surfactant as the
early selective treatment [12].
On the other hand, the best criteria for surfactant
treatment in the perinatal period are unknown, and thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Endpoint of the clinical study in early and late
treatment groups
Early
treatment
Late
treatment
P
(n = 33) (n = 27)
MV and/or death < 7 days, number (%) 7 (21) 17 (63) 0.0013
MV and/or death prior to discharge,
number (%)
9 (27) 19 (70) 0.004
MV prior to discharge, number (%) 8 (25) 17 (68) 0.005
a/APO2 after 6 hours, mean ± SD 0.48 ± 0.18 0.36 ± 0.18 0.02
Patent ductus arteriosus, number (%) 10 (30) 16 (59) 0.02
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tant treatment is ongoing. Verder et al. demonstrated
in 1999 that early treatment with surfactant (median
age 5.5 hours of life), administered during a short
period of intubation to infants with an a/APO2 of
0.35 - 0.22 (FiO2 of 0.37- 0.55), in comparison with late
treatment (median age 9.9 hours of life) in infants with an
a/APO2 of 0.21 – 0.15 (FiO2 of 0.57– 0.77), decreased the
need for MV and/or mortality [13]. The most recent
guidelines recommend that babies with RDS should
be given rescue surfactant early in the course of the
disease [14].
The hypothesis of this study is that a strategy of early
treatment with surfactant, in addition to being clinically
more effective, is also economically advantageous in
comparison to a strategy of late treatment. To test this
hypothesis we performed an economic evaluation of the
two strategies using clinical data from the Verder et al.
study [13] and costs calculated in the Neonatal Intensive
Care Unit of an Italian hospital.
Materials and methods
The reference study
The cost-effectiveness analysis was carried out analysing
the results of the randomised controlled Verder et al.
study [13]. In this study it was shown that treatment of
infants of <30 weeks gestational age using the INSURE
(INtubation-SURfactant-Extubation) procedure with sur-
factant (Curosurf® 200 mg/kg, Chiesi Farmaceutici SpA,
Parma, Italy), performed early (5.2 hours of life), at an
a/APO2 value of 0.35-0.22, equal to FiO2 of 0.37-0.55, sig-
nificantly reduces [21% vs. 63%, p <0.005] the need for MV
or mortality during the first 7 days of life compared to late
treatment (9.9 hours old), performed at an a/APO2 value
of 0.21-0.15, equal to an FiO2 of 0.57-0.77 [13]. Table 1
shows the clinical features of patients assigned to the two
treatment groups; the patients did not show significant
differences at randomisation. In Table 2 the primary and
secondary endpoints are shown and other variables that
showed significant differences between the two groups.
Lastly, Table 3 shows the duration of oxygen therapy, of
NCPAP and of MV in the two treatment groups.Table 1 Clinical characteristics of patients at
randomisation
Early treatment Late treatment P
(n = 33) (n = 27)
Weight at birth (grams) 950 (665–1600) 935 (618–1555) 0.84
Gestational age (weeks) 27 (25–29) 28 (25–29) 0.54
Age (hours) 4.1 (0.3-40.1) 4.5 (1.7-41.3) 0.55
a/APO2 0.28 (0.22-0.38) 0.28 (0.08-0.77) 0.69
TcPCO2 (mm Hg) 50 (34–103) 47 (30–74) 0.69
The values are expressed as median and (range).Methods
We conducted the (incremental) cost-effectiveness ana-
lysis of early strategy compared to late strategy to assess
clinical efficacy and costs of the principal healthcare re-
sources employed during hospitalisation for respiratory
care, with the purpose of analyzing them by the hospital
perspective of direct medical costs. In particular, the
costs of the surfactant, the depreciation of the ventila-
tors used and all the consumable materials needed for
respiratory assistance, as well as the medical and nursing
staff costs, were taken account of. The latter costs were
calculated taking account of the average time needed to
perform the various relief operations (e.g., endotracheal
aspiration).
Other direct medical costs related to treatment were
not considered, as assumed to be similar for the two
therapeutic approaches in consideration (early vs. late)
[15]. All costs were estimated in Euro (€) relating to the
year 2013. The clinical efficacy and the costs estimated
both occurred during the period of hospital admission
which, based on what was reported in the clinical trial of
reference [13], concluded in a period of time of less than
one year. For this reason costs were estimated at the
current value without applying any discount rate [15,16].
Consumption and costing of health resources
According to what was shown in the Verder et al. study
[13], the surfactant (Curosurf®, Chiesi Farmaceutici SpA,
Parma, Italy) was administered at a dose of 200 mg/kg
for the first time. Given an average weight at birth of
950 grams for the early group and 935 grams for the lateTable 3 Duration of oxygen therapy, NCPAP and MV in
“early” and “late” treatment groups
Early treatment Late treatment P
(n = 33) (n = 27)
Oxygen therapy (days) 6.5 (0.3-69) 18.5 (0.5-64) 0.54
NCPAP (days) 38.5 (0.8-64) 39.0 (12–155) 0.76
MV (days) 2.5 (1.2-5.5) 2.1 (0.3-13.9) 0.47
The values are expressed as median and (range).
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tant was on average equal to 190 grams (33/33 pa-
tients,100%) and 187 grams (18/27 patients, 67%) in the
two groups respectively. The second dose was instead
equal to 100 mg/kg and administered in 9% (3/33) of
early group infants and 11% (3/27) of late group infants.
As the weight of the infants was not known at the time
of the second dose, an average of 95 mg dose of surfac-
tant for the early group and 93.5 mg for the late group
was estimated, based on weight at birth [13]. The acqui-
sition cost of the surfactant was calculated based on the
hospital final purchase price updated to July 2013 and
equal to Euro 2.31 per milligram of product.
The daily cost of treatment with NCPAP or MV was
calculated with reference to what was highlighted by a
previous study [17], thanks to which it was possible to
estimate the consumable materials and duration of doc-
tor/nurse assistance needed to perform NCPAP or MV,
distinguishing between the first day, during which the
circuit is installed (for NCPAP and for MV), and subse-
quent days, when maintenance and monitoring of venti-
lation systems is performed instead. Tables 4 and 5
respectively show the costs of NCPAP and of MV, differ-
entiating between the first and subsequent days and tak-
ing account of the type and quantities of consumable
materials used, as well as the unit costs and the time
employed by professionals (doctor and nurse).Table 4 Unit cost of materials and of care staff for treatment
Unit costs First day
Consumable materials (n)
Ventilator* € 1.37 1
Patient ventilator circuit € 95.83 1
Canopy for gas humidification € 12.71 1
Hood for generator € 20.32 1
Nasal mask for generator € 17.90 1
500 ml H2O humidifier € 0.85 1
Gold/nasal disposable aspiration tube € 0.32 8
Anti-decubitus nasal hydrocolloid plaques € 0.60 1
Consumable materials total
Staff (minutes)
Mounting of ventilator and circuit € 0.43 15
Positioning (5 minutes x 8 times) € 0.43 40
Gold pharyngeal aspiration (8 asp.) € 0.43 15
Direct care and equipment monitoring € 0.43 100
Radiography (1 die) € 0.43 10
Substitution of respiratory circuit € 0.43 -
Staff care total
Total
*Infant Flow® SiPAP System, San Diego, CA, USA.The daily depreciation cost of the ventilation system,
amounting to Euro 1.37 for NCPAP and Euro 9.59 for
MV, was calculated by reference to the hospital purchase
price (NCPAP: Infant Flow® SiPAP System, San Diego,
CA, USA, Euro 5,000; MV: Leoni Plus®, Heinen + Low-
enstein, Bad Ems, Germany, Euro 35,000) divided by the
duration of the asset depreciation process (10 years,
equivalent to 3,650 days). All other materials used for
the provision of NCPAP or MV were costed based on
their market prices. For the costing of staff, only the
presence of a professional nurse was considered in treat-
ment with NCPAP, while for MV, the professional figure
of a doctor, when required, was also considered. The
hourly cost for professionals, as indicated by the Italian
national labour collective agreement, was calculated at
Euro 26.00 for the nurse (cost per minute Euro 0.43) and
Euro 60.00 for the doctor (cost per minute Euro 1.00).
The cost of NCPAP was calculated by multiplying the
number of days of service provision (early group:
38.5 days; late group: 39 days) by the unit cost (distin-
guishing between the first and subsequent days) multi-
plied by the frequency of the event itself, which in this
specific case was of 100% of patients in both groups.
The same method of calculation was used to determine
the average cost of MV per patient, which showed a dif-
ferent frequency (early group: 25%; late group: 68%) and
duration (early group: 2.5 days; late group: 2.1 days)with NCPAP (%)
First day cost Subsequent days Subsequent days cost
(n)
€ 1.37 1 € 1.37
€ 95.83 0.17 € 15.97
€ 12.71 0.17 € 2.12
€ 20.32 - -
€ 17.90 - -
€ 0.85 1 € 0.85
€ 2.56 8 € 2.56
€ 0.60 - -
€ 152.13(66) € 22.87(21)
(minutes)
€ 6.50 - -
€ 17.33 40 € 17.33
€ 6.50 15 € 6.50
€ 43.33 100 € 43.33
€ 4.33 10 € 4.33
- 35 € 15.08
€ 78.00(34) € 86.58(79)
€ 230.13 € 109.45
Table 5 Unit cost of materials and of care staff for treatment with MV (%)
Unit costs First day First day cost Subsequent days Subsequent days cost
Consumable materials (n) (n)
Ventilator* € 9.59 1 € 9.59 1 € 9.59
Leoni Plus patient ventilator circuit € 104.54 1 € 104.54 0.17 € 17.42
Endotracheal tube € 1.06 1 € 1.06 0.5 € 0.53
500 ml H2O humidifier € 0.85 1 € 0.85 1 € 0.85
Closed circuit for E.T. aspiration € 13.18 1 € 13.18 0.5 € 6.59
Gold/nasal disposable aspiration tube € 0.32 8 € 2.56 8 € 2.56
Disposable syringe (for sedation) € 0.21 1 € 0.21 1 € 0.21
Set for i.v. infusion (for sedation) € 0.20 1 € 0.20 1 € 0.20
Consumable materials total € 132.19(57) € 37.95(28)
Staff (minutes) (minutes)
Mounting of ventilator and circuit € 0.43 15 € 6.50 - -
Positioning (5 minutes x 8 times) € 0.43 40 € 17.33 40 € 17.33
E.T. aspiration (3 – 8 asp.) € 0.43 20 € 8.67 20 € 8.67
Gold pharyngeal aspiration (8 asp.) € 0.43 15 € 6.50 15 € 6.50
Direct care and equipment monitoring € 0.43 60 € 26.00 60 € 26.00
Continuous intravenous sedation € 0.43 15 € 6.50 15 € 6.50
Radiography (2 die) € 0.43 20 € 8.67 20 € 8.67
Intubation assistance** € 1.00/0.43 20 € 20.00 20 € 8.76
Substitution of respiratory circuit € 0.43 - - 35 € 15.08
Staff care total € 100.17(43) € 97.41(72)
Total € 232.35 € 135.36
*Leoni Plus®, Heinen + Lowenstein, Bad Ems, Germany.
**Doctor assistance is expected on the first day (costed at an hourly cost of € 60.00), while for subsequent days the assistance of nursing staff only is assumed
(costed at an hourly cost of € 26.00).
Table 6 Comparison of cost-effectiveness (€) in “early”
and “late” treatment groups
Early
treatment
Late
treatment
Difference
Primary Endpoint
MV and/or death < 7 days, (%) 21 63 42
Average cost per patient treated
- surfactant (1st. dose) 438.56 287.76 150.80
- surfactant (2nd. dose) 19.93 23.98 4.05
- NCPAP 4,334.36 4,389.08 54.72
- MV 108.85 259.25 150.40
Total 4,901.70 4,960.07 58.37
Dani et al. Italian Journal of Pediatrics 2014, 40:40 Page 4 of 7
http://www.ijponline.net/content/40/1/40between the two groups. To check the effects of a
change in value of the main variables in calculation of
early and late strategy costs, we simulated the effects of
a change of plus or minus 15% and 30% in the costs of
NCPAP and of MV. In addition, we simulated the effects
of an increase of 15%, 30% or 50% in the number of pa-
tients who required MV and of the MV duration in the
early group.
Results
The cost of consumable material was greater for NCPAP
(Euro 152.13) than for MV (Euro 132.19) for the first
day of treatment, while for subsequent days it was
greater for MV (Euro 22.87 vs. Euro 37.95). The cost of
staff was greater for MV compared to NCPAP both for
the first day (Euro 100.17 vs. Euro 78.00) and for subse-
quent days (Euro 97.41 vs. Euro 86.58). The overall cost
of the first day of treatment was equal to Euro 230.13
for NCPAP and Euro 232.35 for MV, while the cost for
each subsequent day was Euro 109.45 for NCPAP and
Euro 135.36 for MV (Tables 4 and 5).
The cost of treatment with surfactant was Euro 438.56
in the early group and Euro 287.76 in the late group,while the cost of MV was Euro 108.85 in the early group
and Euro 259.25 in the late group. The average cost for
patients treated with the early strategy was moderately
lower than for patients treated with the late strategy
(Euro 4,901.70 vs. Euro 4,960.07), a difference of Euro
58.37 (Table 6).
The simulation of changes in the cost of NCPAP and
MV were associated always with a lower cost for early
strategy compared to late strategy. The simulation of an
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and of MV duration in the group was associated always
with a lower early strategy cost compared to late strat-
egy cost (Table 7).
Because early treatment was the dominant therapeutic
option since more effective and less costly than late
treatment (Table 7), it was not necessary to calculate the
incremental cost-effectiveness ratio between the two al-
ternatives considered here.
Discussion
The objective of this study was the analysis of the costs
(hospital’s perspective) of two strategies of surfactant ad-
ministration, early vs. late, proposed in the Verder et al.
study [13], using the experience of an Italian NICU for
calculation of the costs. In particular, only the costs as-
sociated with treatment of respiratory failure in preterm
infants with RDS were considered, i.e., those costs re-
lated to administration of surfactant and to the fre-
quency and duration of NCPAP and/or MV treatment,
as these represent the most important difference in care
that emerged between the two treatment alternatives.
We have shown that the costs of early treatment (Euro
4,901.70) are substantially similar (slightly lower) thanTable 7 One-way (univariate) sensitivity analysis
Parameter “Early” treatment
Base case
MV and/or death < 7 days, (%)* 21
Average cost per treated patient (€) 4,901.70
Variation in Mechanical Ventilation cost
- plus 15% compared to base case (€) 4,918.03
- minus 15% compared to base case (€) 4,885.37
- plus 30% compared to base case (€) 4,934.35
- minus 30% compared to base case (€) 4,869.05
Variation in NCPAP cost
- plus 15% compared to base case (€) 5,551.85
- minus 15% compared to base case (€) 4,251.55
- plus 30% compared to base case (€) 6,202.01
- minus 30% compared to base case (€) 3,601.39
% ET patients with MV
- plus 15% compared to base case (€) 4,918.03
- plus 30% compared to base case (€) 4,934.35
- plus 50% compared to base case (€) 4,956.12
ET patient days in MV
- plus 15% compared to base case (€) 4,914.39
- plus 30% compared to base case (€) 4,927.08
- plus 50% compared to base case (€) 4,944.00
*For calculation of the cost-effectiveness ratio the reciprocal of the estimated given
patients that do not undergo MV and/or death within seven days of birth equal tothose of late treatment (Euro 4,960.07). For this reason,
considering that the Verder study [13] demonstrated
greater clinical efficacy of early treatment, reducing the
frequency of MV and/or mortality, this result further
confirms the benefits of such a strategy and supports its
application.
Analysing the costs in detail, it may be observed how
in the early group the cost of treatment with surfactant
is greater (Euro 458.49 vs. Euro 311.74). However, this is
offset by the higher cost of treatment with MV in the
late group (Euro 259.25 vs. Euro 108.85), because in this
group the frequency of MV (68% vs. 25%) was higher. In
both groups the main cost is represented by NCPAP,
equal to 88% of the total cost, an expected result consid-
ering that all the enrolled patients received this treat-
ment, the duration of which was similar in the two
groups (39 vs. 38.5 days).
Analysing the NCPAP and MV costs, it is interesting
to note that the cost of material for the first day of treat-
ment is greater for NCPAP than for MV, while for sub-
sequent days the opposite occurs. With regard to the
cost of staff, this is greater in MV than in NCPAP, both
in the first and subsequent days. Of importance also is
how the cost of staff decreases after the first day of MV“Late” treatment Difference (€) C/E analysis result
Dominant
63 −42
4,960.07 - 58.37
4,998.95 - 80.93 Dominant
4,921.18 - 35.81 Dominant
5,037.84 −103.49 Dominant
4,882.29 - 13.25 Dominant
5,618.43 - 133.57 Dominant
4,301.70 - 50.16 Dominant
6,276.79 - 74.78 Dominant
3,643.34 - 41.95 Dominant
4,960.07 - 42.04 Dominant
4,960.07 - 25.71 Dominant
4,960.07 - 3.94 Dominant
4,960.07 - 45.68 Dominant
4,960.07 - 32.99 Dominant
4,960.07 - 16.07 Dominant
efficacy by the Verder et al. study was considered [12], i.e., the percentage of
79% for the ET group and 37% for the LT group was considered.
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mary, the cost of material for beginning NCPAP is
greater than for beginning MV, while the cost of material
for continuing NCPAP is less; the cost of staff for begin-
ning and continuing MV is greater than for beginning
and continuing NCPAP.
To evaluate and confirm these results it would have
been very useful to have been able to compare them
with other similar studies, but unfortunately a similar
cost analysis of respiratory support with surfactant,
NCPAP and MV in preterm infants with RDS has never
been carried out before.
To work around this limitation and therefore attempt
to confirm our results, we carried out a simulation of
different scenarios in which the cost of NCPAP and of
MV was increased or decreased by 15% and by 30% and
the frequency and duration of NCPAP and of MV in-
creased by 15%, 30% and 50%. Even in these cases, the
early strategy was found to be the dominant alternative
(Table 7).
A limitation of this economic analysis may be in hav-
ing used the clinical results of a study carried out in
Denmark [13], which may not be transferable to the
Italian population. This choice was justified by a short-
age in the literature of randomised controlled trials that
compare the efficacy of early vs. late surfactant treat-
ment. In fact, of the six published studies two were per-
formed using synthetic surfactant [18,19] and two using
bovine surfactant [20,21], while in Italy only porcine
surfactant is commercially available. Furthermore, an-
other study was conducted in a cohort of patients who
were all in MV with high frequency oscillatory ventila-
tion (HFOV) [22], while none of these studies [18-22]
included the use of the INSURE procedure, widely used
in Italy [23]. Therefore, the Verder study [13], both for
the type of surfactant used as well as for the manage-
ment of respiratory failure, is the one which can be
considered most similar to the management of preterm
infant RDS in our country, even though the thresholds
of early (FiO2 of 0.37-0.55) and late (FiO2 of 0.57-0.77)
treatment are far greater than those currently in use
in Italy.
Conclusions
Despite its simplifications, the cost-effectiveness analysis
performed in this study demonstrates how early treatment
with surfactant of preterm infants with RDS is not only
more effective clinically, but is also economically cheaper
than late treatment. In fact, the greater initial costs of
early treatment with surfactant are compensated by subse-
quent lower costs required for MV. These results must
find confirmation, however, in future randomised and
controlled studies that can perform a comparison in a
prospective mode.Competing interests
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